Patents Represented by Attorney Bill T. Brazil
  • Patent number: 6942802
    Abstract: The present invention relates to the purification of polypeptides and the removal of endotoxin via immobilized metal affinity chromatography (IMAC). More specifically, the invention relates to methods for removing bacterial endotoxin in a protein solution. In specific embodiments, the invention relates to the elimination of endotoxin from Moraxella catarrhalis outer membrane proteins.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: September 13, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Rhonda Lunt Sundberg, Robert Leonard Hopfer
  • Patent number: 6899885
    Abstract: A protein from M. catarrhalis, designated the 74 kD protein, is isolated and purified. The 74 kD protein has an amino-terminal amino acid sequence which is conserved among various strains of M. catarrhalis. The protein has a molecular weight of approximately 74.9 kD as measured on a 10% SDS-PAGE gel, while its molecular weight as measured by mass spectrometry is approximately 74 kD. The 74 kD protein is used to prepare a vaccine composition which elicits a protective immune response in a mammalian host, to protect the host against disease caused by M. catarrhalis.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: May 31, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Dexiang Chen, Karl R. VanDerMeid, John C. McMichael, Vicki L. Barniak
  • Patent number: 6867000
    Abstract: A method for inducing and enhancing protective and/or therapeutic immunity in a mammal to HSV includes the steps of at least one immunization with an effective amount of a DNA vaccine composition which comprises a first nucleic acid molecule comprising a DNA sequence encoding the HSV type 1 or type 2 gD protein, and a second nucleic acid molecule comprising a DNA sequence encoding each Interleukin-12 heterodimer subunit. The method also comprises at least one subsequent immunization with an effective amount of a protein vaccine composition which comprises the HSV type 1 or type 2 gD protein; and the IL-12 heterodimer. A local anesthetic may be included in the DNA vaccine composition in an amount that forms one or more complexes with the nucleic acid molecules. When provided to the mammal in suitable effective dosages according to this protocol, the vaccine compositions used in this method produce an unexpectedly good protective and/or therapeutic immune response against HSV in an immunized mammal.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: March 15, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Eric M. Mishkin, Robert J. Natuk, Michael W. Pride, Maninder K. Sidhu
  • Patent number: 6664068
    Abstract: The present invention relates, at least in part, to polypeptides which include Bcl-xL binding domains, novel Bcl-xL binding domains of Pablo polypeptides, nucleic acid molecules encoding such polypeptides, and uses thereof. For example, such polypeptides and nucleic acid molecules are useful in modulating apoptosis, particularly in neural cells, as well as in the treatment or prevention of disorders that can benefit from modulation of cell death.
    Type: Grant
    Filed: April 4, 2002
    Date of Patent: December 16, 2003
    Assignee: Wyeth
    Inventors: Robert Mark, Kathleen H. Young, Andrew T. Wood
  • Patent number: 6511845
    Abstract: This invention provides a method of protecting a primate from an infectious organism by stimulating the production of antibodies or cell mediated immunity to the infectious organism which comprises administering to said primate intranasally, intramuscularly, or subcutaneously, live recombinant adenoviruses in which the virion structural protein is unchanged from that in the native adenovirus from which the recombinant adenovirus is produced, and which contain the gene coding for the antigen corresponding to said antibodies or inducing said cell mediated immunity. Preferably, the infectious organism is HIV and the primate is a human.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: January 28, 2003
    Inventors: Alan R. Davis, Paul P. Hung, Michael D. Lubeck, Robert J. Natuk, Pranab K. Chanda, Shridhara C. S. Murthy, Shaw-Guang L. Lee
  • Patent number: 6482804
    Abstract: A soluble ionic complex is formed by an aqueous mixture of a benzylammonium group-containing surfactant and a polynucleic acid sequence. When the mixture forms a vesicular complex, the sequence is packaged therein. This composition is useful in pharmaceutical compositions and in methods of delivering the polynucleic acid sequence (which preferably encodes a protein or peptide) to a cell for expression. Such methods are useful in therapy, as vaccines and as gene therapy agents.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: November 19, 2002
    Assignee: Wyeth
    Inventors: Shankar Musunuri, Chandrasekhar Satishchandran
  • Patent number: 6461618
    Abstract: A protein from the M. catarrhalis designated the 74 kD protein is isolated and purified. The 74 kD protein has an amino-terminal amino acid sequence which is conserved among various strains of M. catarrhalis. The protein has a molecular weight of approximately 74,9 kD as measured on a 10% SDS-PAGE gel, while its molecular weight as measured by mass spectrometry is approximately 74 kD. The 74 kD protein is used to prepare a vaccine composition which elicits a protective immune response in a mammalian host to protect the host again disease caused by M. catarrhalis.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 8, 2002
    Assignee: American Cyanamid Company
    Inventors: Dexiang Chen, Karl R. VanDerMeid, John C. McMichael, Vicki L. Barniak